000			01571nam a2200337Ia 4500
001			ocm52452348
003			OCoLC
005			20180312141842.0
007			he bmb024bbca
008			030618s2003 dcua bb f000 0 eng d
020			_a0160697115
020			_a9780160697111
040			_aFPS _beng _cFPS _dOCLCQ _dFCMBL _dOCLCQ _dOCLCO _dOCLCQ _dGPO _dMvI
074			_a1019-B-01 (MF)
088			_aSerial no. 107-143 (United States. Congress. House. Committee on Energy and Commerce)
086	0		_aY 4.C 73/8:107-143
099			_aY 4.C 73/8:107-143
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Oversight and Investigations.
245	1	0	_aIssues relating to the safety of Accutane : _bhearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, December 11, 2002.
260			_aWashington : _bU.S. G.P.O. : _bFor sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office], _c2003.
300			_aiii, 739 pages : _billustrations ; _c24 cm
336			_atext _btxt _2rdacontent
337			_amicroform _bh _2rdamedia
338			_amicrofiche _bhe _2rdacarrier
500			_aShipping list no.:2003-0253-M.
504			_aIncludes bibliographical references.
500			_a"Serial no. 107-143."
500			_aCRDP Program record.
533			_aMicrofiche. _bWashington : _cSupt. of Docs., U.S. G.P.O., _d2003. _e10 microfiches : negative.
650		0	_aIsotretinoin _xSide effects.
650		0	_aIsotretinoin _xToxicology.
999			_c269573 _d269573